Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu

A vaccinia virus, improved technology, applied in the direction of viruses, antiviral agents, viral antigen components, etc., can solve the problems of unsuitability for preparation and application to humans, and achieve the effect of reducing the dose of vaccines

Inactive Publication Date: 2010-01-27
PAUL EHRLICH INST BUNDESAMT FU
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently, such potent adjuvant formulations are considered unsuitable for preparation and application in humans, and thus vaccines that do not require adjuvants for enhancing their immunogenicity are favorable candidates for future vaccine development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
  • Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
  • Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0083] Preparation of the vaccine

[0084] The H5N1 virus was propagated in MDCK cells, and viral RNA was extracted from the culture supernatant using a high-purity RNA isolation kit (Roche, Almere, the Netherlands). Subsequently, cDNA was synthesized from vRNA using Superscript reverse transcriptase (Invitrogen, Carlsbad, California, USA) and 5'-AGCAAAAGCAGG-3' (SEQ ID NO. 9) oligonucleotide (Eurogentec, Seraing, Belgium) as a primer . Next, using Pfu (Pyrococcus furiosus, Stratagene, La Jolla, California, USA) as a thermostable DNA polymerase, the HA gene sequence was amplified by polymerase chain reaction. The primer sequence was extended using NotI and XhoI restriction sites to facilitate directional cloning to the cloning plasmid pBluescriptSK+ (Stratagene, La Jolla, California, USA).

[0085] The HA gene sequence was prepared from these plasmids by NotI / XhoI digestion, treated with Klenow polymerase to generate sticky ends, and cloned into the PmeI site of the MVA expressio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament in particular a vaccine, wherein the sequence of heterologous nucieic acid is from influenza A virus class H5 antigen. In a further aspect of the invention the invention relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein (a) the heterologous nucleic acid is incorporated into a non-essential site within the genome of MVA, (b) the heterologous nucleic acid is under the control of a vaccinia virus promoter, or orthopoxvirus promoter, or poxvirus-specific promoter and, (c) the heterologous nucleic acid is selected from the group of nucleic acids encoding a gene or a part of a gene from an influenza A virus class H5.

Description

Background of the invention [0001] Since the first case of human H5N1 infection appeared in 1997, this subtype of influenza virus has continuously caused outbreaks of fowl disease worldwide, which is related to the gradual accumulation of the number of birds spreading to humans. As of September 14, 246 human cases have been recorded, 144 of which proved to be fatal (WHO disease alert 2006. Confirmed human cases of avian influenza H5N1 (confirmed human cases of avian influenza H5N1)-http: / / www.who .int / csr / disease / avian_influenza / country / cases_table_2007_10_17 / en / index.html, accessed October 17th, 2007). In addition, H5N1 virus infection has spread from Southeast Asia to other continents of the world (WHO.2007.Affected areas with confirmed cases of H5N1 avian influenza since 2003), status as of 08.10. 2007). Because these viruses not only infect birds but also various mammals (Vahlenkamp, ​​TW, and TCHarder. 2006. Influenza virus infections in mammals. Berl Munch Tierarztl Woch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/145A61K38/00A61K39/00
CPCC12N2710/24143A61K39/145C12N2760/16134A61K2039/5254A61K2039/5256A61K39/12A61P31/12A61P31/16A61P37/00A61K48/00
Inventor 亚瑟米恩·苏泽尔约翰尼斯·洛尔格尔德·苏特尔A·D·M·E·奥斯特豪G·F·瑞米埃尔兹万尤斯特·科瑞特兹
Owner PAUL EHRLICH INST BUNDESAMT FU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com